On March 18, 2024, Cingulate Inc., a company listed on the Nasdaq Capital Market under the symbol CING, announced an increase in the maximum aggregate offering price of its common stock from $4,970,000 to $8,470,000. This adjustment was made under the At The Market Offering Agreement with H.C. Wainwright & Co., which was originally dated January 3, 2023. The company has also filed a prospectus supplement for an additional $3,500,000 in shares. Previously, Cingulate Inc. had sold shares totaling $4,969,120 under the same agreement. Concurrently, the company has received a waiver from a February 2024 offering purchaser, leading to an amendment in the exercise price and term of Series A and Series B Warrants issued in September 2023. The exercise price for these warrants has been reduced to $1.13, and the exercise terms have been extended to March 17, 2029, for Series A Warrants, and to March 17, 2026, for Series B Warrants.

On March 18, 2024, Cingulate Inc., a company listed on the Nasdaq Capital Market under the symbol CING, announced an increase in the maximum aggregate offering price of its common stock from $4,970,000 to $8,470,000. This adjustment was made under the At The Market Offering Agreement with H.C. Wainwright & Co., which was originally dated January 3, 2023. The company has also filed a prospectus supplement for an additional $3,500,000 in shares. Previously, Cingulate Inc. had sold shares totaling $4,969,120 under the same agreement. Concurrently, the company has received a waiver from a February 2024 offering purchaser, leading to an amendment in the exercise price and term of Series A and Series B Warrants issued in September 2023. The exercise price for these warrants has been reduced to $1.13, and the exercise terms have been extended to March 17, 2029, for Series A Warrants, and to March 17, 2026, for Series B Warrants.